Dr Pisano shares insights on expanding dermatologists' comfort with immunotherapy through collaborative learning and collective expertise.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Pisano stated dermatologists are very aware of immunotherapy efficacy in advanced cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) from prominent journal coverage. However, solo dermatology practitioners may hesitate to directly administer immunotherapy. She emphasized that dermatologists play key roles in setting patient expectations around neoadjuvant/palliative intent, managing cutaneous adverse effects to enable treatment continuation, and identifying severe reactions necessitating discontinuation. Hamid discussed how immunotherapy toxicities present a “black box” for subspecialists inexperienced with these agents. While serious adverse events are uncommon, serious endocrine, gastrointestinal, and cardiac immune-related adverse events can still occur and may appear long after treatment cessation. He stressed the importance of educating the care team on immune-mediated adverse effects at treatment initiation and through the course of therapy, as unfamiliarity causes heightened anxiety around managing symptoms relative to clinicians well-versed in immunotherapy. Hamid concluded by saying that cross-disciplinary meetings focused on adverse event profiles, timing, and management can build expertise.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More